News

Advarra Vice President of Institutional Services & Strategic Consulting James Riddle contributed to InSite, The Global Journal for Clinical Research Sites in the article Site Solutions Summit Reflections: A Regulatory Look into Virtual Trials.

Advarra has updated its IRB Handbook for Investigators, Institutions, Sponsors, and Sponsors’ Representatives to incorporate Canadian regulations and to update certain policies and processes to align with current practices.

The Association of Clinical Research Professionals (ACRP) has appointed Sergio Armani, Advarra VP of Business Development, to its Board of Trustees. The appointment is effective January 1, 2020.

Advarra’s offices will be closed Wednesday, December 25, through Wednesday, January 1. During this time, the IRB and IBC will not meet.

Advarra Director of Biosafety Services Dan Eisenman recently contributed to an article in Lab Manager Magazine

Advarra is pleased to announce the intent to acquire Forte, the industry’s leading provider of standards-based clinical research technology solutions.

Advarra Chief Compliance Officer and Institutional Official Michele Russell Einhorn was recently featured in Bloomberg Law on Your Fitbit Data Means New Ethics Conundrums for Clinical Trials.

Advarra’s Regulatory and Operations teams will be out of office on September 16 and 17, 2019, for an off-site, team customer service training.

Transaction to Accelerate Growth in Industry-Leading Compliance Business Focused on Increasing Safety and Efficiency in Clinical Trials

Advarra announced today that it has been selected by the Institute for Advanced Clinical Trials for Children (I-ACT for Children) to provide central institutional review board (IRB) services to the organization’s pediatric clinical trial site network.

NIH OSP has revised the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules to eliminate duplicative regulatory oversight.

On May 1, 2019, all new studies submitted will be managed under Advarra’s FDA/OHRP registration. All studies previously under Quorum Review FDA/OHRP registration will fall under the Advarra FDA/OHRP registration once the RIB oversight transfer is complete.